HWHG: The injectable remimazolam benzenesulfonate has received a drug registration certificate for new indications

HWHG announced that its holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. recently received the "Drug Registration Certificate" for injectable remimazolam besylate approved by the National Medical Products Administration. The new indication for this drug is: "used as a sedative during mechanical ventilation in intensive care." Injectable remimazolam besylate is a new type of benzodiazepine developed jointly by Yichang Renfu and the German company PAION, and it is an ultra-short-acting GABAa receptor agonist. So far, approximately RMB 20 million has been invested in this project. The market sales of this drug are expected to be around RMB 250 million in 2024. The approval of this new indication is beneficial for expanding the usage scope of this product and will have a positive impact on the company